Biosimilar Leaders Compliment Pfizer For Calling Out Fellow Innovators, But Should FDA Play A Role To Dispel Misinformation?
Executive Summary
Industry speakers at AAM's GRx and Biosims conference discussed whether FDA should play a role, or whether education should fall solely on the shoulders of sponsors.
You may also be interested in...
Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.
From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive
The agency is being urged to help spur biosimilar development and market success by finalizing guidance on interchangeability, enhancing public education efforts, and taking a more forceful approach to combating misinformation, while reference product sponsors want FDA to adopt 'umbrella' exclusivity to encourage innovative changes in novel biologics.
Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior
Citizen petition requests agency guidance that specifies what communications are false and misleading; Pfizer cites a Janssen Remicade brochure and Amgen YouTube video that suggest switching to biosimilars could lead to different outcomes.